REGN 3048

Drug Profile

REGN 3048

Alternative Names: REGN3048

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Viral protein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 12 Feb 2018 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in USA (IV) (NCT03301090) (Regeneron pipeline, May 2018)
  • 02 Oct 2017 Regeneron Pharmaceuticals plans a NIH-sponsored phase I trial for Middle East respiratory syndrome coronavirus by the end of 2017
  • 22 Aug 2016 Regeneron Pharmaceuticals enters into a collaboration agreement with Sanofi to develop human monoclonal antibodies for Middle East respiratory syndrome coronavirus before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top